American Medical Association statement on antibody treatments

Community NewsNews
293

Translate to Spanish or other 102 languages!

We are pleased that the FDA is following the scientific evidence and limiting the use of monoclonal antibody treatments to those that are effective against the Omicron variant. Image for illustration purposes.
We are pleased that the FDA is following the scientific evidence and limiting the use of monoclonal antibody treatments to those that are effective against the Omicron variant. Image for illustration purposes.

Mega Doctor News

- Advertisement -

Gerald E. Harmon, M.D.
President, American Medical Association

“Given the latest data showing the Omicron variant of SARS-CoV-2 is responsible for 99% of current COVID-19 infections, we are pleased that the FDA is following the scientific evidence and limiting the use of monoclonal antibody treatments to those that are effective against the Omicron variant. Limiting the use of these treatments will help ensure patients receive the best available therapy. We encourage physicians to reference the current National Institutes of Health (NIH) COVID-19 treatment guidelines for the latest information on authorized therapies and recommendations for their use.

“We continue to strongly urge every eligible individual to make sure they are up to date on their COVID-19 vaccinations, including booster doses. The Omicron variant is highly contagious and the unvaccinated remain most at risk of severe illness, hospitalization and death if infected. Data further suggests that a booster dose provides greater protection against the Omicron variant.”

- Advertisement -
- Advertisement -

Latest news

- Advertisement -
Previous article
What drives vaccine hesitancy?
Next article
Long-acting Antibody Treatment vs. Omicron Variant in Patients with Compromised Immune System

More Articles

DHR Health Expands Cancer Care Services with Radiation Oncologist, Dr. Jason Shumadine Wolff

DHR Health, one of the largest physician-owned hospitals in the United States and a proud healthcare provider for the Rio Grande Valley since 1997, is delighted to welcome Dr. Jason Shumadine Wolff, to its growing network of specialty care physicians.

Study Reveals Link Between Parent and Child Weight Is Mostly Genetic

The link between parents’ body mass index (BMI) and their children’s BMI in childhood is driven largely by genetic inheritance, rather than by any direct biological effects of parental weight during pregnancy, a new study suggests.

DHR Health Continues to Lead the Way in Treatment of Alzheimer’s Disease for the RGV

Two years after DHR Health announced it was the first hospital south of San Antonio to successfully administer Leqembi, an FDA-approved intravenous treatment for early Alzheimer’s disease, DHR Health continues to expand access to advanced Alzheimer’s care for patients in the Rio Grande Valley being now the only facility doing amyloid PET Scans, a diagnostic test to accurately diagnose Alzheimer’s disease. DHR Health also offers Kisunla, another FDA-approved intravenous treatment for early symptomatic Alzheimer’s disease.

The Genetic Armor Defeating Colorectal Cancer

A team of scientists from the Barbara Ann Karmanos Cancer Institute, Wayne State University, and institutions across the U.S., have published a landmark paper on the role of TGFBR1*6A, a naturally occurring genetic mutation in the TGFBR1 gene found in approximately 14 percent of the general population. Image for illustration purposes
- Advertisement -